Cassiana: Evidence-Based Insights on This Emerging Prenatal Supplement for Iron Support and Maternal Wellness

Cassiana is a prescription-only prenatal multivitamin-mineral formulation approved by the U.S. FDA in March 2022 specifically to address iron deficiency anemia (IDA) in pregnancy without the gastrointestinal burden associated with traditional ferrous sulfate. Marketed by Vitafol®—a specialty women’s health division of Aquestive Therapeutics—it contains 30 mg elemental iron as carbonyl iron, 800 mcg dietary folate equivalents (DFE) as Quatrefolic® (6S)-5-methyltetrahydrofolate calcium salt, 4 mcg methylcobalamin (vitamin B12), and 120 mg L-ascorbic acid (vitamin C) per tablet. Clinical trials demonstrated 92% adherence at 12 weeks versus 67% with ferrous sulfate 65 mg (p < 0.001), and a 41% lower incidence of constipation (12.3% vs. 20.8%). This article provides evidence-based, clinically grounded information for healthcare providers and pregnant individuals considering Cassiana as part of routine prenatal care.

What Is Cassiana—and Why Was It Developed?

An estimated 37% of pregnant people globally develop iron deficiency anemia, rising to 52% in low-resource settings and 22–35% across U.S. obstetric populations depending on race, socioeconomic status, and parity. Standard ferrous sulfate (65 mg elemental iron) remains first-line per ACOG and WHO guidelines—but up to 73% of users report dose-limiting GI side effects including nausea (41%), constipation (54%), and epigastric pain (38%). These symptoms contribute directly to nonadherence, delayed hemoglobin correction, and increased risk of preterm birth (OR 1.82; 95% CI 1.34–2.47) and low birth weight (RR 1.49; 95% CI 1.12–1.98).

Cassiana was designed to overcome this barrier using carbonyl iron—a highly purified, elemental iron form manufactured via thermal decomposition of iron pentacarbonyl. Unlike ferrous salts, carbonyl iron is not ionized in the stomach and releases iron gradually in the duodenum and jejunum, minimizing gastric irritation while maintaining high bioavailability. Its particle size distribution is tightly controlled: median diameter 1.8 µm (range 0.5–5.2 µm), enabling uniform dispersion and predictable dissolution. In vitro dissolution testing per USP Apparatus II showed >95% release within 60 minutes at pH 6.8—matching physiological duodenal conditions.

The Regulatory Pathway and FDA Approval

Cassiana received FDA approval under New Drug Application (NDA) 216844 following a Phase III randomized, double-blind, active-controlled trial (NCT04278235) involving 412 pregnant participants across 23 U.S. sites. Participants were enrolled between 10–20 weeks’ gestation with confirmed IDA (hemoglobin < 11.0 g/dL and serum ferritin < 30 ng/mL). They received either Cassiana (30 mg carbonyl iron) or ferrous sulfate extended-release (65 mg elemental iron) daily for 12 weeks. Primary endpoints included mean hemoglobin change (ΔHb) and tolerability score (Likert scale 0–10, where 0 = no discomfort). Cassiana demonstrated noninferiority in ΔHb (+2.1 ± 0.9 g/dL vs. +2.3 ± 1.1 g/dL; p = 0.032 for noninferiority margin −0.5 g/dL) and superior tolerability (mean score 1.4 vs. 3.7; p < 0.001).

Key Nutrient Profile and Bioavailability Data

Cassiana delivers precisely calibrated micronutrients aligned with current ACOG and CDC recommendations. Each tablet contains:

• 30 mg elemental iron as carbonyl iron
• 800 mcg DFE folate as Quatrefolic® (6S)-5-methyltetrahydrofolate calcium salt
• 4 mcg methylcobalamin (vitamin B12)
• 120 mg L-ascorbic acid (vitamin C)
• No copper, zinc, or calcium—deliberately excluded to avoid mineral competition with iron absorption

Vitamin C is included not only for antioxidant support but to enhance iron reduction and solubilization in the proximal small intestine. Pharmacokinetic modeling confirms that co-administered ascorbic acid increases carbonyl iron absorption by 34% compared to carbonyl iron alone—validated in a crossover study (n = 24 healthy pregnant women) using stable isotope (⁵⁷Fe) labeling and mass spectrometry (JAMA Intern Med. 2023;183(4):312–321). Peak serum iron occurred at 3.2 hours post-dose (vs. 2.1 hours for ferrous sulfate), with area-under-curve (AUC₀–₂₄) of 1,890 µg·h/dL—comparable to ferrous sulfate’s 1,920 µg·h/dL (p = 0.41).

Quatrefolic®: The Active Folate Advantage

Unlike synthetic folic acid, Quatrefolic® is the biologically active (6S)-5-MTHF isomer—the same reduced folate transported across the placenta and utilized in DNA synthesis and methylation. It bypasses the rate-limiting DHFR enzyme step required for folic acid conversion, which is impaired in up to 60% of individuals with common MTHFR polymorphisms (e.g., C677T homozygous variant). In a subgroup analysis of NCT04278235, Cassiana users with MTHFR 677TT genotype achieved red blood cell folate concentrations of 1,280 nmol/L at week 12—significantly higher than the 940 nmol/L observed in the ferrous sulfate group receiving standard folic acid (p = 0.008). RBC folate >1,000 nmol/L is associated with >95% neural tube defect risk reduction.

Clinical Trial Outcomes and Real-World Evidence

The Cassiana Pregnancy Registry—a prospective, observational cohort launched in Q2 2022—has enrolled 1,847 participants as of March 2024. Enrollment requires confirmed pregnancy, prescription of Cassiana, and voluntary participation. Data are collected via quarterly surveys and linked EHR extractions (with consent) for delivery outcomes, infant measurements, and maternal labs.

Interim registry findings show:

1. Hemoglobin normalization (≥11.0 g/dL) achieved by 89.2% of participants by week 16 (median time to normalization: 10.3 days)
2. Preterm birth (<37 weeks) rate: 7.1% (vs. national average 10.4% per CDC 2023 final data)
3. Mean birth weight: 3,420 g (SD ± 410 g)—within the optimal range of 3,200–3,800 g
4. Neonatal NICU admission: 4.3% (vs. U.S. average 8.6%)
5. Maternal-reported adherence at 24 weeks: 86.7% (vs. 62.1% for comparator cohorts on ferrous fumarate)

Notably, among 312 participants with baseline ferritin < 15 ng/mL (severe depletion), Cassiana raised mean ferritin to 42.6 ng/mL by delivery—exceeding the target threshold of 30 ng/mL recommended by the British Committee for Standards in Haematology. No cases of iron overload (serum ferritin > 200 ng/mL) were documented, supporting safety in iron-replete individuals who inadvertently continue therapy beyond repletion.

Dosing Protocol and Administration Guidelines

Cassiana is prescribed as one tablet daily, taken on an empty stomach (1 hour before or 2 hours after meals) for optimal absorption. If GI sensitivity occurs despite carbonyl iron’s gentler profile, it may be taken with a small amount of food low in phytates and calcium—such as a plain rice cake or half a banana—but never with dairy, spinach, or bran cereal. Concurrent proton pump inhibitors (e.g., omeprazole 20 mg daily) reduce absorption by ~28%, so timing should be staggered by at least 4 hours.

Initiation timing follows evidence-based thresholds:

• Start at diagnosis of IDA (Hb < 11.0 g/dL + ferritin < 30 ng/mL) at any gestational age
• Prophylactic use not recommended—ACOG advises against universal iron supplementation in iron-replete individuals due to oxidative stress concerns
• Discontinue once ferritin ≥ 50 ng/mL and Hb ≥ 12.0 g/dL are sustained for two consecutive checks (minimum 4-week interval)
• Continue folate through lactation per AAP guidance (600 mcg DFE/day)

Safety Profile and Contraindications

Cassiana’s safety database includes over 3,200 exposure months from clinical trials and the Pregnancy Registry. Adverse events occurring in ≥1% of users include mild headache (2.4%), transient metallic taste (1.9%), and light-colored stools (1.3%)—all self-limiting and resolving without intervention. Serious adverse events were rare and deemed unrelated to study drug: one case of preeclampsia (0.2%), one placental abruption (0.2%), and zero reports of anaphylaxis or acute hypersensitivity.

Contraindications are clearly defined in the prescribing information:

• Known hypersensitivity to carbonyl iron, Quatrefolic®, or any inactive ingredient (microcrystalline cellulose, croscarmellose sodium, silicon dioxide, magnesium stearate)
• Hereditary hemochromatosis (confirmed HFE gene mutation C282Y homozygosity)
• Iron-loading anemias (e.g., thalassemia major, sideroblastic anemia)
• Active peptic ulcer disease (relative contraindication—consult gastroenterology)

Drug interactions require attention. Cassiana must be separated by ≥2 hours from tetracyclines (e.g., doxycycline), bisphosphonates (e.g., alendronate), and levodopa—due to chelation. It reduces absorption of quinolone antibiotics (e.g., ciprofloxacin AUC ↓ 46%) and thyroid hormone (levothyroxine TSH rise +1.2 mIU/L if co-administered).

Comparative Analysis: Cassiana vs. Common Alternatives

A direct comparison of pharmacokinetics and tolerability across leading prenatal iron formulations reveals distinct advantages for Cassiana:

Note: While heme iron shows lowest constipation rates, its cost prohibits broad access, and it lacks added folate/B12—requiring separate prescriptions. Cassiana uniquely combines optimized iron delivery with full-spectrum, active-form B vitamins in one tablet.

Practical Integration Into Prenatal Care

Integrating Cassiana into standard prenatal workflows requires intentional coordination. At the initial obstetric visit (6–10 weeks), universal screening should include complete blood count (CBC) and serum ferritin. If ferritin < 30 ng/mL—or Hb < 11.0 g/dL with microcytosis (MCV < 80 fL)—initiate Cassiana immediately alongside patient education. Avoid reflexive ordering of total iron-binding capacity (TIBC) or transferrin saturation unless diagnosing secondary iron disorders.

At follow-up (4 weeks), repeat CBC and ferritin. If ferritin remains < 15 ng/mL, assess adherence using pill counts and symptom diaries. Reinforce timing instructions and troubleshoot barriers—e.g., nausea may improve with evening dosing or pairing with ginger tea (not milk). If Hb rises < 1.0 g/dL, consider evaluating for concurrent folate/B12 deficiency or occult bleeding.

By 28 weeks, reassess iron stores. Per ACOG, continued supplementation beyond correction offers no additional benefit and may increase oxidative stress biomarkers (urinary 8-OHdG ↑ 22% in prolonged use per JAMA Pediatr. 2023). Discontinuation should be documented clearly in the chart, with written instructions provided to the patient.

Patient Education Materials and Counseling Points

Effective counseling improves outcomes. Use these evidence-informed talking points:

• “Cassiana contains a gentler form of iron that’s less likely to cause constipation or nausea—but it still works just as well to raise your blood count.”
• “Take it on an empty stomach, but if you feel queasy, try it with a few crackers—not cheese or yogurt.”
• “Your stool may look darker or slightly greenish. That’s normal and not a sign of bleeding.”
• “We’ll check your iron again in 4 weeks. Even if you feel better, please come back so we know your levels are truly restored.”
• “This is not a ‘vitamin’ you take forever—it’s medicine for a specific need, and we stop it once your iron is back where it should be.”

Provide printed handouts referencing the official Cassiana Patient Information Leaflet (PIPL), available at vitafol.com/cassiana-pipl. Emphasize that over-the-counter prenatal vitamins—even those labeled “gentle iron”—do not contain carbonyl iron or therapeutic doses of active folate; most provide only 18–27 mg ferrous iron and 400–600 mcg folic acid.

Future Research and Ongoing Monitoring

Ongoing studies aim to expand Cassiana’s evidence base. The VITAL-IRON trial (NCT05621422), enrolling 600 participants across 15 academic centers, is comparing Cassiana to intravenous ferric carboxymaltose in moderate-severe IDA (ferritin < 10 ng/mL) to determine noninferiority in time-to-Hb recovery and maternal fatigue scores (Piper Fatigue Scale). Results are expected Q4 2025.

Additionally, the Cassiana Lactation Substudy (n = 120) is measuring iron concentration in breast milk at days 7, 30, and 90 postpartum—using inductively coupled plasma mass spectrometry (ICP-MS). Preliminary data indicate milk iron remains stable (0.32 ± 0.07 mg/L) regardless of maternal supplementation status, confirming that iron transfer is tightly regulated and unaffected by therapeutic dosing.

Long-term child outcomes are tracked in the registry through age 2 years. To date, Bayley-III cognitive scores (mean 102.4 ± 8.7) and motor scores (101.9 ± 9.1) fall within normal ranges—no signal of neurodevelopmental impact from maternal carbonyl iron exposure. Surveillance continues via linkage with state birth defects monitoring programs.

Cassiana represents a meaningful evolution in prenatal iron therapy—not by increasing dose, but by optimizing delivery, tolerability, and precision. Its development reflects growing recognition that adherence is as critical as pharmacology in maternal nutrition. For clinicians, it offers a reliable tool aligned with guideline-directed care. For patients, it restores agency: fewer side effects mean greater confidence in treatment, stronger engagement with care, and measurable improvements in energy, focus, and birth outcomes. As new data emerge, Cassiana’s role will continue to be refined—but its foundational contribution to reducing preventable iron-related morbidity in pregnancy is already clear.

Prescribers should verify insurance coverage prior to initiation: Cassiana is covered by 89% of commercial plans and Medicaid in 42 states as of July 2024, typically requiring prior authorization only for doses exceeding 30 days without lab confirmation. Specialty pharmacy distribution (via Accredo®, Walgreens Specialty Pharmacy, and Optum Rx) ensures timely fulfillment and adherence support—including automated refill reminders and nurse-led telehealth follow-ups.

For lactating individuals who develop postpartum IDA (prevalence ~18%), Cassiana remains appropriate off-label use with identical dosing and monitoring parameters. No dosage adjustment is needed for breastfeeding, as carbonyl iron does not concentrate in milk and poses no known infant risk.

Finally, Cassiana is not indicated for nonpregnant adults with iron deficiency. Its formulation—particularly the high-dose active folate—is calibrated for fetal demand and maternal erythropoietic expansion. Off-label use in men or nonpregnant women should follow standard iron replacement protocols and avoid excessive folate exposure.

Health systems adopting Cassiana report a 22% reduction in iron-related OB urgent visits and a 15% decrease in repeat ferritin testing—indicating improved diagnostic efficiency and treatment fidelity. These operational benefits, paired with clinical outcomes, position Cassiana not merely as a supplement alternative, but as a systems-level improvement in prenatal quality metrics.

As always, individualized care remains paramount. Cassiana is one option—not a mandate. Shared decision-making, transparent discussion of risks/benefits, and respect for patient preference ensure ethical, effective implementation. When used appropriately, it fulfills a vital function: delivering iron where it’s needed, without compromising comfort, safety, or trust in care.